Teva Pharm. USA, Inc. v. Sandoz Inc. (In Re Copaxone Consol. Cases)
906 F.3d 1013
Fed. Cir.2018Background
- Patentees: Yeda (assignee) and Teva own four "Copaxone" patents claiming a 40 mg glatiramer acetate (GA) regimen administered as three subcutaneous injections over seven days (40 mg, 3x/week) to treat relapsing-remitting MS; earliest priority date Aug. 20, 2009.
- Prior art: multiple clinical studies (Bornstein, Teva Phase III, Flechter, Cohen, FORTE, Khan 2008/Caon) established 20 mg daily efficacy, tested 40 mg doses, and explored less-than-daily schedules (every-other-day or less) with evidence of comparable efficacy and improved tolerability/adherence.
- Pinchasi (Teva WO application) disclosed 40 mg every other day; FORTE and Cohen supported 40 mg safety/efficacy; FDA records and studies encouraged exploring less frequent dosing to reduce injection burden.
- District court construed certain claim phrases (e.g., "the regimen being sufficient…") as non-limiting statements of intended effect and held all asserted claims obvious under 35 U.S.C. § 103; Teva appealed claim construction and obviousness findings.
- On review, the Federal Circuit affirmed: it upheld the non-limiting construction, sustained the district court’s factual findings (motivation to combine dose and frequency; reasonable expectation of success), and affirmed invalidity for obviousness, including dependent claims directed to improved tolerability and reduced severity/frequency of injection reactions.
Issues
| Issue | Plaintiff's Argument (Teva) | Defendant's Argument (Appellees) | Held |
|---|---|---|---|
| Claim construction: Are "sufficiency" / "reduced frequency/effectiveness" phrases limiting? | Phrases are claim limitations added during prosecution and should limit scope. | Phrases are non-limiting statements of intended result (superfluous to express dosing steps). | Court: Phrases are non-limiting (like Bristol‑Myers); affirmed. |
| Obviousness of 40 mg, 3x/week regimen | Combination was not obvious; reliance on hindsight and improper "obvious-to-try" analysis; unpredictable PK/PD and mechanism preclude reasonable expectation of success. | Prior art limited viable doses (20 mg, 40 mg) and encouraged less-frequent dosing; finite, predictable permutations made 40 mg 3x/week obvious to try with reasonable expectation of success. | Court: Affirmed obviousness; prior art provided motivation and reasonable expectation of success; KSR analysis appropriate. |
| Obviousness of improved tolerability / reduced frequency of ISRs/IPIRs | Prior art did not support an expectation that 3x/week would improve tolerability versus 20 mg daily. | Studies (Khan 2008, Caon, Flechter) and common sense: fewer injections reduce frequency of injection reactions and improve adherence. | Court: Affirmed obviousness of frequency/tolerability limitations; factual findings not clearly erroneous. |
| Obviousness of reduced severity of injection-site reactions (’776 patent) | Frequency evidence cannot establish reduced severity; severity is distinct. | Evidence of reduced lipoatrophy (a severe ISR) and expert testimony tied reduced frequency to reduced severity. | Court: Affirmed obviousness of severity claims; Caon and expert testimony gave reasonable expectation. |
Key Cases Cited
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (claim construction uses ordinary meaning to POSITA with primary reliance on intrinsic evidence)
- Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576 (Fed. Cir. 1996) (primacy of intrinsic evidence in claim construction)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (U.S. 2007) (obvious‑to‑try doctrine when finite predictable solutions and market/design pressure)
- Bristol‑Myers Squibb Co. v. Ben Venue Labs., Inc., 246 F.3d 1368 (Fed. Cir. 2001) (statements of intended result are non‑limiting)
- In re Cyclobenzaprine Hydrochloride Extended‑Release Capsule Patent Litig., 676 F.3d 1063 (Fed. Cir. 2012) (bioequivalence and unpredictability of PK/PD can limit obviousness findings)
- Hoffmann‑La Roche Inc. v. Apotex Inc., 748 F.3d 1326 (Fed. Cir. 2014) (reasonable expectation of success, not absolute predictability, suffices for obviousness)